Jan S Moreb
Overview
Explore the profile of Jan S Moreb including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
64
Citations
1934
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Moreb J, Lantos L, Chen F, Elliott K, Dugan J, Skarbnik A, et al.
Transfus Apher Sci
. 2023 Sep;
62(6):103787.
PMID: 37704508
With the use of plerixafor in addition to growth factor for peripheral blood stem cell mobilization, the yield of autologous stem cell harvest has been higher while the length of...
2.
Yang G, Singh S, McDonough C, Lamba J, Hamadeh I, Holliday L, et al.
Clin Pharmacol Ther
. 2021 Aug;
110(6):1558-1569.
PMID: 34390503
Medication-related osteonecrosis of the jaw (MRONJ) is a rare but serious drug-related adverse event. To identify pharmacogenomic markers of MRONJ associated with bisphosphonate therapy, we conducted a genomewide association study...
3.
Tantawy M, Chekka L, Huang Y, Garrett T, Singh S, Shah C, et al.
Front Cardiovasc Med
. 2021 May;
8:645122.
PMID: 33996940
Multiple myeloma (MM) is the second most frequent hematologic cancer in the United States. Carfilzomib (CFZ), an irreversible proteasome inhibitor being used to treat relapsed and refractory MM, has been...
4.
Rajasurya V, Elliott K, Dugan J, Moreb J
Leuk Res Rep
. 2020 Dec;
15:100232.
PMID: 33318925
No abstract available.
5.
Richardson P, Oriol A, Larocca A, Blade J, Cavo M, Rodriguez-Otero P, et al.
J Clin Oncol
. 2020 Dec;
39(7):757-767.
PMID: 33296242
Purpose: Melphalan flufenamide (melflufen) is a first-in-class peptide-drug conjugate that targets aminopeptidases and rapidly and selectively releases alkylating agents into tumor cells. The phase II HORIZON trial evaluated the efficacy...
6.
Cogle C, Collins B, Turner D, Pettiford L, Bosse R, Hawkins K, et al.
Br J Haematol
. 2020 Apr;
189(5):e211-e213.
PMID: 32236943
No abstract available.
7.
Liu Z, Zhang S, Horn B, Moreb J
Clin Transplant
. 2020 Jan;
34(3):e13797.
PMID: 31997402
Postautologous stem cell transplantation (ASCT) engraftment syndrome (ES) is a well-known clinical complication; however, many aspects remain largely controversial. In this retrospective study, we reviewed records of 156 ASCTs done...
8.
Khan A, Muzaffar J, Murthy H, Wingard J, Moreb J
Case Rep Hematol
. 2019 Aug;
2019:1548610.
PMID: 31467738
[This corrects the article DOI: 10.1155/2018/9052314.].
9.
Drusbosky L, Singh N, Hawkins K, Salan C, Turcotte M, Wise E, et al.
Blood Adv
. 2019 Jun;
3(12):1837-1847.
PMID: 31208955
Patients with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) are generally older and have more comorbidities. Therefore, identifying personalized treatment options for each patient early and accurately is essential....
10.
Yang G, Singh S, Chen Y, Hamadeh I, Langaee T, McDonough C, et al.
Bone
. 2019 Apr;
124:75-82.
PMID: 31022475
Osteonecrosis of the jaw (ONJ) is a rare but serious drug induced adverse event, mainly associated with the use of antiresorptive medications, such as intravenous (IV) bisphosphonates (BPs) in cancer...